European LeukemiaNet clinical signs and symptoms as prognostic markers in polycythemia vera during ruxolitinib

European LeukemiaNet defines the clinical signs and symptoms (CSSs) of polycythemia vera (PV) as progressive splenomegaly, leukocytosis, thrombocytosis, inadequate hematocrit control, and cardiovascular risk factors. In PV patients receiving hydroxyurea, CSSs indicate a phenotype with higher thrombosis risk across the standard risk categories. However, the prognostic value of CSSs for thrombosis or progression to secondary myelofibrosis (SMF) or acute leukemia (AL) during second-line ruxolitinib therapy remains unknown. We assessed the incidence rate ratios (IRRs) of thrombosis and disease progression during ruxolitinib treatment, and the prognostic impact of CSSs at treatment initiation, in 254 PV patients from the PV-ARC multicenter cohort. CSSs were identified in 50.4% of patients, with similar proportions in low- and high-risk groups (50% vs 50.5%). The IRRs for thrombosis and progression to SMF/AL were 1.0 and 4.2 %p‑y, respectively. Conventional thrombotic risk categories did not predict thrombosis or progression. In contrast, CSSs were associated with higher IRRs of both thrombosis (1.8 vs 0 %p‑y, p = 0.05) and progression (6.0 vs 2.3 %p‑y, p = 0.02). Persistent or progressive leukocytosis was the strongest predictor of disease progression. In conclusion, CSSs refine conventional risk stratification by improving prediction of thrombosis and disease progression during ruxolitinib, supporting their integration into routine clinical assessment.

Authors

Institutions

Publication Details

Journal
Leukemia
Published
2026-11-17
DOI
https://doi.org/10.1038/s41375-026-03183-y
Primary Topic
Myeloproliferative Neoplasms: Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

European LeukemiaNet clinical signs and symptoms as prognostic markers in polycythemia vera during ruxolitinib

Fabrizio Cavalca, Francesca Palandri, Roberto Latagliata, Monica Crugnola et al.
5 links
Leukemia
Myeloproliferative Neoplasms: Diagnosis and Treatment
article

European LeukemiaNet clinical signs and symptoms as prognostic markers in polycythemia vera during ruxolitinib

Fabrizio Cavalca, Francesca Palandri, Roberto Latagliata, Monica Crugnola, Alessia Tieghi, Chiara Sartor, Mario Tiribelli, Francesco Lanza, Daniela Cilloni, Giulia Benevolo, Mirko Farina, Alessandra D’Addio, Emilia Scalzulli, Valerio De Stefano, Fabrizio Pane, Francesco Mendicino, Giuseppe Alberto Palumbo, Gianni Binotto, Erika Morsia, Novella Pugliese, Daniele Cattaneo, Massimo Breccia, Filippo Branzanti, Elena Maria Elli, Florian Heinrich Heidel, Flavia Salvatore, Alessandra Dedola, Elena Rossi
article en

Abstract

European LeukemiaNet defines the clinical signs and symptoms (CSSs) of polycythemia vera (PV) as progressive splenomegaly, leukocytosis, thrombocytosis, inadequate hematocrit control, and cardiovascular risk factors. In PV patients receiving hydroxyurea, CSSs indicate a phenotype with higher thrombosis risk across the standard risk categories. However, the prognostic value of CSSs for thrombosis or progression to secondary myelofibrosis (SMF) or acute leukemia (AL) during second-line ruxolitinib therapy remains unknown. We assessed the incidence rate ratios (IRRs) of thrombosis and disease progression during ruxolitinib treatment, and the prognostic impact of CSSs at treatment initiation, in 254 PV patients from the PV-ARC multicenter cohort. CSSs were identified in 50.4% of patients, with similar proportions in low- and high-risk groups (50% vs 50.5%). The IRRs for thrombosis and progression to SMF/AL were 1.0 and 4.2 %p‑y, respectively. Conventional thrombotic risk categories did not predict thrombosis or progression. In contrast, CSSs were associated with higher IRRs of both thrombosis (1.8 vs 0 %p‑y, p = 0.05) and progression (6.0 vs 2.3 %p‑y, p = 0.02). Persistent or progressive leukocytosis was the strongest predictor of disease progression. In conclusion, CSSs refine conventional risk stratification by improving prediction of thrombosis and disease progression during ruxolitinib, supporting their integration into routine clinical assessment.

Leukemia
Università Cattolica del Sacro Cuore (IT), Marche Polytechnic University (IT), University of Udine (IT), University of Padua (IT), Agostino Gemelli University Polyclinic (IT), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), Medizinische Hochschule Hannover (DE), University of Catania (IT), Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT), Azienda Sanitaria Unità Locale di Reggio Emilia (IT), Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT), Azienda Unità Sanitaria Locale Della Romagna (IT), Federico II University Hospital (IT), Istituto di Ematologia di Bologna (IT), Azienda USL di Bologna (IT), Ospedale di Belcolle (IT), Ospedale Annunziata di Cosenza (IT), University of Turin (IT), University of Naples Federico II (IT), University of Brescia (IT), Sapienza University of Rome (IT), University of Bologna (IT)
Ministero della Salute
Good health and well-being
Myeloproliferative Neoplasms: Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon